|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects chemical synthesis |
ISO |
[10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA CYP3A4 protein affects the chemical synthesis of 10-hydroxywarfarin |
CTD |
PMID:16035367 PMID:20735727 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein; [10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; [10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:20735727 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
10-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein; 10-hydroxywarfarin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Zidovudine]; [10-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine |
CTD |
PMID:25393417 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:20735727 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein; [4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; [4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:20735727 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
4'-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein; 4'-hydroxywarfarin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Zidovudine]; [4'-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine |
CTD |
PMID:25393417 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Adrm1 |
ADRM1 26S proteasome ubiquitin receptor |
decreases expression |
ISO |
4-hydroxycoumarin results in decreased expression of ADRM1 mRNA |
CTD |
PMID:18492274 |
|
NCBI chr 3:167,265,435...167,270,197
Ensembl chr 3:167,265,296...167,270,195
|
|
G |
Glo1 |
glyoxalase 1 |
decreases activity |
ISO |
4-hydroxycoumarin analog results in decreased activity of GLO1 protein |
CTD |
PMID:33989593 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
ISO |
4-hydroxycoumarin results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:18492274 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Pxn |
paxillin |
decreases expression decreases phosphorylation affects localization |
ISO |
4-hydroxycoumarin results in decreased expression of PXN mRNA alternative form; 4-hydroxycoumarin results in decreased expression of PXN protein alternative form 4-hydroxycoumarin results in decreased phosphorylation of PXN protein 4-hydroxycoumarin affects the localization of PXN protein |
CTD |
PMID:18492274 |
|
NCBI chr12:41,060,791...41,107,952
Ensembl chr12:41,060,791...41,107,931
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
4-hydroxycoumarin results in decreased expression of RAC1 protein |
CTD |
PMID:18492274 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases metabolic processing affects metabolic processing |
EXP |
UGT1A6 protein results in increased metabolism of 4-hydroxycoumarin UGT1A6 gene polymorphism affects the metabolism of 4-hydroxycoumarin |
CTD |
PMID:9429234 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
decreases activity multiple interactions |
ISO |
4-hydroxycoumarin results in decreased activity of VKORC1 protein 4-hydroxycoumarin inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1] |
CTD |
PMID:29581108 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
multiple interactions decreases activity |
ISO |
4-hydroxycoumarin inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] 4-hydroxycoumarin results in decreased activity of VKORC1L1 protein |
CTD |
PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects export |
ISO |
ABCG2 protein affects the export of Hymecromone analog |
CTD |
PMID:15598971 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Hymecromone inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:24661945 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Hymecromone inhibits the reaction [Dietary Fats results in decreased activity of CAT protein] |
CTD |
PMID:24661945 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Hymecromone inhibits the reaction [Dietary Fats results in increased activity of CYP2E1 protein] |
CTD |
PMID:24661945 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO EXP |
SULT1A1 protein results in increased sulfation of Hymecromone |
CTD |
PMID:11181495 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
Hymecromone affects the activity of TP53 protein; Hymecromone metabolite affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions increases metabolic processing increases activity increases glucuronidation |
ISO |
[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A1 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; belinostat inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]; Diclofenac inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Diclofenac inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]; Estradiol promotes the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]; licochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT1A1 protein]; osimertinib inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]; pterostilbene inhibits the reaction [[UGT1A1 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:15378558 PMID:15593333 PMID:15802387 PMID:26875642 PMID:31812603 PMID:33290829 PMID:34044055 More...
|
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases activity increases metabolic processing multiple interactions increases glucuronidation |
ISO |
Hymecromone results in increased activity of UGT1A3 protein UGT1A3 protein results in increased metabolism of Hymecromone [UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A3 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; Androsterone inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Androsterone inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Hymecromone]; belinostat inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Hymecromone]; licochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT1A3 protein]; pterostilbene inhibits the reaction [[UGT1A3 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:15802387 PMID:26875642 PMID:31812603 PMID:33290829 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
affects metabolic processing increases activity multiple interactions increases metabolic processing increases glucuronidation |
EXP ISO |
UGT1A6 gene polymorphism affects the metabolism of Hymecromone Hymecromone results in increased activity of UGT1A6 protein [UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A6 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; belinostat inhibits the reaction [[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A6 protein results in increased glucuronidation of Hymecromone]; bisphenol A inhibits the reaction [UGT1A6 protein results in increased glucuronidation of Hymecromone]; Diclofenac inhibits the reaction [[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Diclofenac inhibits the reaction [UGT1A6 protein results in increased glucuronidation of Hymecromone]; licochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT1A6 protein]; pterostilbene inhibits the reaction [[UGT1A6 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:9429234 PMID:15802387 PMID:18214896 PMID:25393417 PMID:26875642 PMID:31812603 PMID:33290829 More...
|
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a7c |
UDP glucuronosyltransferase 1 family, polypeptide A7C |
increases glucuronidation |
EXP |
UGT1A7 protein results in increased glucuronidation of Hymecromone |
CTD |
PMID:15502008 |
|
NCBI chr 9:88,739,577...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
EXP |
UGT1A8 protein results in increased glucuronidation of Hymecromone |
CTD |
PMID:15502008 |
|
NCBI chr 9:88,727,094...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation increases metabolic processing increases activity multiple interactions |
ISO |
UGT1A9 protein results in increased glucuronidation of Hymecromone UGT1A9 protein results in increased metabolism of Hymecromone Hymecromone results in increased activity of UGT1A9 protein [UGT1A9 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A9 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; Diclofenac inhibits the reaction [[UGT1A9 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Diclofenac inhibits the reaction [UGT1A9 protein results in increased glucuronidation of Hymecromone]; licochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT1A9 protein]; pterostilbene inhibits the reaction [[UGT1A9 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:15378558 PMID:15802387 PMID:26875642 PMID:31812603 PMID:33290829 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2a1 |
UDP glucuronosyltransferase family 2 member A1 |
increases glucuronidation |
ISO |
UGT2A1 protein results in increased glucuronidation of Hymecromone |
CTD |
PMID:21164388 |
|
NCBI chr14:20,521,018...20,545,934
Ensembl chr14:20,517,951...20,545,531
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
increases glucuronidation increases activity increases metabolic processing multiple interactions |
EXP ISO |
UGT2B1 protein results in increased glucuronidation of Hymecromone UGT2B17 protein results in increased glucuronidation of Hymecromone Hymecromone results in increased activity of UGT2B17 protein UGT2B17 protein results in increased metabolism of Hymecromone [UGT2B17 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; licochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT2B17 protein] |
CTD |
PMID:8302279 PMID:8798464 PMID:26875642 PMID:33290829 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases metabolic processing |
EXP |
UGT2B15 protein results in increased metabolism of Hymecromone |
CTD |
PMID:7574722 |
|
NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases activity increases glucuronidation increases metabolic processing multiple interactions |
ISO |
Hymecromone results in increased activity of UGT2B7 protein UGT2B7 protein results in increased glucuronidation of Hymecromone UGT2B7 protein results in increased metabolism of Hymecromone [UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT2B7 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; Androsterone inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Androsterone inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Hymecromone]; belinostat inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Hymecromone]; licochalcone A inhibits the reaction [Hymecromone results in increased activity of UGT2B7 protein]; pterostilbene inhibits the reaction [[UGT2B7 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:26875642 PMID:31812603 PMID:33290829 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A1 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; belinostat inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Diclofenac inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; pterostilbene inhibits the reaction [[UGT1A1 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:31812603 PMID:33290829 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A3 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; Androsterone inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; pterostilbene inhibits the reaction [[UGT1A3 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:31812603 PMID:33290829 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
ISO |
[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A6 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; belinostat inhibits the reaction [[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; Diclofenac inhibits the reaction [[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; pterostilbene inhibits the reaction [[UGT1A6 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:31812603 PMID:33290829 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
[UGT1A9 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT1A9 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; Diclofenac inhibits the reaction [[UGT1A9 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; pterostilbene inhibits the reaction [[UGT1A9 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:31812603 PMID:33290829 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
multiple interactions |
ISO |
[UGT2B17 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide |
CTD |
PMID:33290829 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; [UGT2B7 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide; Androsterone inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; pterostilbene inhibits the reaction [[UGT2B7 protein results in increased metabolism of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide] |
CTD |
PMID:31812603 PMID:33290829 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Slc22a19 |
solute carrier family 22, member 19 |
multiple interactions |
EXP |
4-methylumbelliferyl sulfate inhibits the reaction [SLC22A19 protein affects the transport of estrone sulfate] |
CTD |
PMID:16079298 |
|
NCBI chr 1:204,910,450...204,965,538
Ensembl chr 1:204,910,455...204,965,538
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
multiple interactions |
EXP |
4-methylumbelliferyl sulfate inhibits the reaction [SLC22A9 protein affects the transport of estrone sulfate] |
CTD |
PMID:18441515 |
|
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
|
|
|
G |
Calr |
calreticulin |
increases activity |
ISO |
4-methylumbelliferyl acetate results in increased activity of CALR protein |
CTD |
PMID:20188080 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions increases hydrolysis |
ISO |
Atropine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-methylumbelliferyl acetate]; Cocaine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-methylumbelliferyl acetate]; tropacocaine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-methylumbelliferyl acetate] |
CTD |
PMID:9311626 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis |
ISO |
CES2 protein results in increased hydrolysis of 4-methylumbelliferyl acetate |
CTD |
PMID:9169443 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Txn1 |
thioredoxin 1 |
increases activity |
ISO |
4-methylumbelliferyl acetate results in increased activity of TXN protein |
CTD |
PMID:24103856 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
4-methylumbelliferyl acetate results in increased expression of VEGFA protein |
CTD |
PMID:24103856 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Car12 |
carbonic anhydrase 12 |
decreases activity |
ISO |
4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA12 protein |
CTD |
PMID:22077347 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car9 |
carbonic anhydrase 9 |
decreases activity |
ISO |
4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA9 protein |
CTD |
PMID:22077347 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
|
G |
Gaa |
alpha glucosidase |
multiple interactions increases metabolic processing |
ISO |
GAA gene SNP inhibits the reaction [GAA protein results in increased metabolism of 4-methylumbelliferyl glucoside] |
CTD |
PMID:21963784 |
|
NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
|
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in decreased expression of BCL2L1 protein |
CTD |
PMID:19061872 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Calr |
calreticulin |
increases activity multiple interactions |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased activity of CALR protein 7,8-diacetoxy-4-methylcoumarin promotes the reaction [CALR protein results in increased acetylation of NOS1 protein] |
CTD |
PMID:20188080 PMID:24103856 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased activity of CASP3 protein |
CTD |
PMID:19061872 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased activity of CASP9 protein |
CTD |
PMID:19061872 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
7,8-diacetoxy-4-methylcoumarin affects the localization of CYCS protein |
CTD |
PMID:19061872 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
7,8-diacetoxy-4-methylcoumarin promotes the reaction [CALR protein results in increased acetylation of NOS1 protein] |
CTD |
PMID:24103856 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased expression of NOS2 |
CTD |
PMID:24103856 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased expression of NOS3 |
CTD |
PMID:24103856 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in decreased expression of PTGS2 protein |
CTD |
PMID:19061872 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
decreases expression |
ISO |
DAMTC decreases expression of RAC1 protein in non-small cell lung cancer cells |
RGD |
PMID:23059821 |
RGD:155791641 |
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
7,8-diacetoxy-4-methylcoumarin inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:19061872 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
7,8-diacetoxy-4-methylcoumarin inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:19061872 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased expression of TP53 protein |
CTD |
PMID:19061872 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
increases activity increases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased activity of TXN protein 7,8-diacetoxy-4-methylcoumarin results in increased expression of TXN mRNA |
CTD |
PMID:24103856 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in decreased expression of TXNIP mRNA |
CTD |
PMID:24103856 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased expression of TXNRD1 mRNA |
CTD |
PMID:24103856 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
7,8-diacetoxy-4-methylcoumarin results in increased expression of VEGFA mRNA; 7,8-diacetoxy-4-methylcoumarin results in increased expression of VEGFA protein |
CTD |
PMID:24103856 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
daphnetin inhibits the reaction [Benzene results in decreased expression of ALB protein] |
CTD |
PMID:33749080 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]; daphnetin inhibits the reaction [sodium arsenite results in increased expression of BAX protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]] daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein] |
CTD |
PMID:30738023 PMID:37209277 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; daphnetin inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]] daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein] |
CTD |
PMID:30738023 PMID:37209277 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein] alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]] |
CTD |
PMID:37209277 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
daphnetin inhibits the reaction [Benzene results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:33749080 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
daphnetin results in increased expression of GCLC protein |
CTD |
PMID:30738023 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
daphnetin results in increased expression of GCLM protein |
CTD |
PMID:30738023 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
daphnetin inhibits the reaction [Benzene results in increased expression of GPT protein] |
CTD |
PMID:33749080 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
daphnetin results in increased expression of HMOX1 protein [sodium arsenite co-treated with daphnetin] results in increased expression of HMOX1 protein; NFE2L2 protein affects the reaction [daphnetin results in increased expression of HMOX1 protein] |
CTD |
PMID:30738023 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
daphnetin inhibits the reaction [Benzene results in increased expression of IL1B protein] daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein] alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]] |
CTD |
PMID:33749080 PMID:37209277 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
daphnetin inhibits the reaction [Benzene results in increased expression of IL2 protein] |
CTD |
PMID:33749080 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
daphnetin inhibits the reaction [Benzene results in increased expression of IL6 protein] daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein] alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]] |
CTD |
PMID:33749080 PMID:37209277 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JAK2 protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JAK2 protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JAK2 protein]] |
CTD |
PMID:37209277 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
ISO |
daphnetin results in decreased expression of KEAP1 protein |
CTD |
PMID:30738023 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
daphnetin results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:30738023 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
daphnetin results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:30738023 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[sodium arsenite co-treated with daphnetin] results in increased expression of NFE2L2 protein; daphnetin results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 protein affects the reaction [daphnetin results in increased expression of HMOX1 protein] |
CTD |
PMID:30738023 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
daphnetin results in increased expression of NQO1 protein |
CTD |
PMID:30738023 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein] |
CTD |
PMID:37209277 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Reg3b |
regenerating family member 3 beta |
multiple interactions |
ISO |
daphnetin inhibits the reaction [Lipopolysaccharides results in increased expression of REG3A protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JAK2 protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] |
CTD |
PMID:37209277 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
multiple interactions |
EXP |
daphnetin inhibits the reaction [Benzene results in increased expression of S1PR1 mRNA] |
CTD |
PMID:33749080 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:37209277 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein] |
CTD |
PMID:37209277 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
daphnetin inhibits the reaction [Benzene results in increased expression of TNF protein] daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein] alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; REG3A protein inhibits the reaction [daphnetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] |
CTD |
PMID:33749080 PMID:37209277 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
ISO |
CYP2E1 protein results in increased metabolism of 7-ethoxycoumarin |
CTD |
PMID:18385292 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases abundance |
EXP |
UGT2B15 protein results in increased abundance of 7-hydroxycoumarin glucuronide |
CTD |
PMID:7574722 |
|
NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589
|
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
7-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein; 7-hydroxywarfarin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Zidovudine]; [7-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine |
CTD |
PMID:25393417 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
affects abundance |
ISO |
VKORC1 gene polymorphism affects the abundance of 7-hydroxywarfarin |
CTD |
PMID:25986145 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1 gene polymorphism affects the susceptibility to Acenocoumarol |
CTD |
PMID:18021343 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Apoe |
apolipoprotein E |
affects response to substance |
ISO |
APOE gene polymorphism affects the susceptibility to Acenocoumarol |
CTD |
PMID:15861030 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects metabolic processing |
ISO |
CYP1A1 protein affects the metabolism of Acenocoumarol |
CTD |
PMID:11918509 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP1A2 protein affects the metabolism of Acenocoumarol |
CTD |
PMID:11918509 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects response to substance |
ISO |
CYP2C18 gene polymorphism affects the susceptibility to Acenocoumarol |
CTD |
PMID:19578179 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
affects metabolic processing |
ISO |
CYP2C19 protein affects the metabolism of Acenocoumarol |
CTD |
PMID:11918509 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
F10 |
coagulation factor X |
decreases activity |
EXP |
Acenocoumarol results in decreased activity of F10 protein |
CTD |
PMID:3490277 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases activity |
EXP |
Acenocoumarol results in decreased activity of F2 protein |
CTD |
PMID:3490277 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
decreases activity |
EXP |
Acenocoumarol results in decreased activity of F5 protein |
CTD |
PMID:3490277 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
F7 |
coagulation factor VII |
decreases activity |
EXP |
Acenocoumarol results in decreased activity of F7 protein |
CTD |
PMID:3490277 |
|
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
|
|
G |
F9 |
coagulation factor IX |
decreases activity |
EXP |
Acenocoumarol results in decreased activity of F9 protein |
CTD |
PMID:3490277 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Ggcx |
gamma-glutamyl carboxylase |
increases activity |
EXP |
Acenocoumarol results in increased activity of GGCX protein |
CTD |
PMID:3490277 |
|
NCBI chr 4:104,469,737...104,485,631
Ensembl chr 4:104,469,765...104,487,063
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
decreases response to substance decreases activity multiple interactions affects response to substance increases response to substance |
ISO |
VKORC1 promoter polymorphism results in decreased susceptibility to Acenocoumarol; VKORC1 protein polymorphism results in decreased susceptibility to Acenocoumarol Acenocoumarol results in decreased activity of VKORC1 protein Acenocoumarol inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1] VKORC1 gene polymorphism affects the susceptibility to Acenocoumarol; VKORC1 gene SNP affects the susceptibility to Acenocoumarol; VKORC1 intron SNP affects the susceptibility to Acenocoumarol; VKORC1 polymorphism affects the susceptibility to Acenocoumarol; VKORC1 protein polymorphism affects the susceptibility to Acenocoumarol VKORC1 protein results in increased susceptibility to Acenocoumarol |
CTD |
PMID:16201835 PMID:16611310 PMID:16869821 PMID:17036862 PMID:18698879 PMID:19578179 PMID:19875892 PMID:25042728 PMID:25866574 PMID:26757860 PMID:28867752 PMID:29581108 More...
|
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
multiple interactions decreases activity |
ISO |
Acenocoumarol inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] Acenocoumarol results in decreased activity of VKORC1L1 protein |
CTD |
PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; aurapten promotes the reaction [ABCB1 protein results in increased import of Daunorubicin] |
CTD |
PMID:18955043 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ccna2 |
cyclin A2 |
affects expression |
ISO |
aurapten affects the expression of CCNA2 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb2 |
cyclin B2 |
affects expression |
ISO |
aurapten affects the expression of CCNB2 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Cdc45 |
cell division cycle 45 |
affects expression |
ISO |
aurapten affects the expression of CDC45 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
affects expression |
ISO |
aurapten affects the expression of CDK1 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
affects expression |
ISO |
aurapten affects the expression of CDKN2B mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
affects expression |
ISO |
aurapten affects the expression of CDKN2C mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Chek1 |
checkpoint kinase 1 |
affects expression |
ISO |
aurapten affects the expression of CHEK1 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
affects expression |
ISO |
aurapten affects the expression of CHEK2 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
EXP |
aurapten results in decreased expression of CTNNB1 protein mutant form |
CTD |
PMID:16012713 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
aurapten inhibits the reaction [DDT results in increased expression of CYP1A1 mRNA]; aurapten inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20865247 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
affects expression |
ISO |
aurapten affects the expression of DDIT3 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
affects expression |
ISO |
aurapten affects the expression of DUSP1 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
E2f1 |
E2F transcription factor 1 |
affects expression |
ISO |
aurapten affects the expression of E2F1 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
affects expression |
ISO |
aurapten affects the expression of E2F2 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
affects expression |
ISO |
aurapten affects the expression of GADD45A mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
aurapten affects the expression of JUN mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kif20b |
kinesin family member 20B |
affects expression |
ISO |
aurapten affects the expression of KIF20B mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
affects expression |
ISO |
aurapten affects the expression of MCM3 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
affects expression |
ISO |
aurapten affects the expression of MCM6 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects response to substance |
ISO |
NFE2L2 protein affects the susceptibility to aurapten |
CTD |
PMID:19150646 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
aurapten inhibits the reaction [DDT results in increased expression of PTGS2 mRNA]; aurapten inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:20865247 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
affects expression |
ISO |
aurapten affects the expression of UHRF1 mRNA |
CTD |
PMID:23320178 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
aurapten inhibits the reaction [DDT results in increased expression of VEGFA mRNA]; aurapten inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] |
CTD |
PMID:20865247 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
multiple interactions decreases activity |
ISO |
coumachlor inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; coumachlor inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide] coumachlor results in decreased activity of VKORC1 protein |
CTD |
PMID:29581108 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
decreases activity multiple interactions |
ISO |
coumachlor results in decreased activity of VKORC1L1 protein coumachlor inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; coumachlor inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide] |
CTD |
PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Coumaphos metabolite results in decreased activity of ACHE protein; Coumaphos results in decreased activity of ACHE protein |
CTD |
PMID:30625376 PMID:33844597 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Coumaphos inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Coumaphos binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Coumaphos binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression |
ISO |
Coumaphos results in increased expression of GPAT3 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Coumaphos results in increased expression of LIF mRNA |
CTD |
PMID:26198647 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Coumaphos binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Coumaphos binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity |
ISO |
Coumaphos results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Coumaphos results in increased expression of SLC7A11 mRNA |
CTD |
PMID:26198647 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Coumaphos binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
Coumaphos metabolite affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
decreases response to substance multiple interactions decreases activity |
EXP ISO |
VKORC1 protein polymorphism results in decreased susceptibility to coumatetralyl coumatetralyl inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1] coumatetralyl results in decreased activity of VKORC1 protein |
CTD |
PMID:27117082 PMID:29581108 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
multiple interactions decreases activity |
ISO |
coumatetralyl inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] coumatetralyl results in decreased activity of VKORC1L1 protein |
CTD |
PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
EXP |
Dicumarol results in decreased activity of AKR1C6 protein |
CTD |
PMID:16788056 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Dicumarol binds to ALB protein |
CTD |
PMID:62049 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of ATM protein modified form] |
CTD |
PMID:26630137 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
[aminochrome 1 co-treated with Dicumarol] results in increased activity of CASP3 protein; Dicumarol promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; Progesterone inhibits the reaction [Dicumarol promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]] Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in decreased expression of CASP3 protein] |
CTD |
PMID:21427056 PMID:21947872 PMID:26630137 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases response to substance multiple interactions |
ISO EXP |
CAT protein results in decreased susceptibility to Dicumarol [Dopamine co-treated with Dicumarol] results in increased expression of CAT mRNA |
CTD |
PMID:11299314 PMID:17040906 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[Dicumarol results in decreased activity of NQO1 protein] inhibits the reaction [Eugenol results in increased expression of CD86 protein] |
CTD |
PMID:21742781 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [diaziquone results in increased expression of CDKN1A mRNA]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Dicumarol inhibits the reaction [RB1CC1 protein results in increased expression of CDKN1A protein] |
CTD |
PMID:9343371 PMID:16061648 PMID:37640247 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]] |
CTD |
PMID:37640247 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
[aminochrome 1 co-treated with Dicumarol] affects the localization of CYCS protein |
CTD |
PMID:21427056 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
Dicumarol promotes the reaction [CYP2E1 protein results in increased reduction of tirapazamine] Dicumarol inhibits the reaction [[CYP2E1 protein co-treated with Paraquat] results in increased expression of KLF6 protein]; Dicumarol inhibits the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein] |
CTD |
PMID:7710944 PMID:22486562 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Drd5 |
dopamine receptor D5 |
increases expression |
EXP |
Dicumarol results in increased expression of DRD5 mRNA |
CTD |
PMID:18522901 |
|
NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
EXP |
Dicoumarol inhibits the reaction [3-(p-azidobenzyl)-4-hydroxycoumarin binds to Fabp1 protein] |
RGD |
PMID:1939124 |
RGD:1626448 |
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Gpr35 |
G protein-coupled receptor 35 |
multiple interactions |
ISO EXP |
Dicumarol binds to and results in increased activity of GPR35 protein |
CTD |
PMID:20919992 |
|
NCBI chr 9:93,527,165...93,539,573
Ensembl chr 9:93,527,127...93,539,299
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [1-nitropyrene results in increased expression of HSPA5 protein] |
CTD |
PMID:19460413 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [IGF1 protein results in increased phosphorylation of JUN protein] |
CTD |
PMID:11278392 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [IL1B protein results in increased expression of TP53 protein] |
CTD |
PMID:17959154 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [IGF1 protein results in increased phosphorylation of JUN protein]; Dicumarol inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein] |
CTD |
PMID:11278392 PMID:17669387 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [[CYP2E1 protein co-treated with Paraquat] results in increased expression of KLF6 protein]; Dicumarol inhibits the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein] |
CTD |
PMID:22486562 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17669387 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions decreases activity |
ISO |
Dicumarol inhibits the reaction [Anisomycin results in increased activity of MAPK10 protein]; Dicumarol inhibits the reaction [Sorbitol results in increased activity of MAPK10 protein]; Dicumarol inhibits the reaction [TRAF2 protein results in increased activity of MAPK10 protein]; NQO1 protein inhibits the reaction [Dicumarol results in decreased activity of MAPK10 protein] |
CTD |
PMID:10531305 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17669387 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein]; Dicumarol inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK8 protein] |
CTD |
PMID:14701702 PMID:24466103 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24466103 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; Dicumarol inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; hydroquinone inhibits the reaction [Dicumarol inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]] |
CTD |
PMID:17669387 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Cadmium Chloride results in increased expression of MT1 mRNA]; Dicumarol inhibits the reaction [zinc chloride results in increased expression of MT1 mRNA]; Dicumarol inhibits the reaction [Zinc Sulfate results in increased expression of MT1 mRNA] |
CTD |
PMID:11551972 PMID:15142038 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Lipopolysaccharides results in increased activity of NFKB1 protein]; Dicumarol inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] |
CTD |
PMID:10531305 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions decreases activity decreases expression affects response to substance |
ISO EXP |
[aristolochic acid I co-treated with Dicumarol] results in increased expression of NQO1 protein; [Dicumarol results in decreased activity of NQO1 protein] inhibits the reaction [Eugenol results in increased expression of CD86 protein]; [Dicumarol results in decreased activity of NQO1 protein] which results in decreased susceptibility to Mitomycin; [Dicumarol results in decreased activity of NQO1 protein] which results in decreased susceptibility to Streptonigrin; aristolochic acid I inhibits the reaction [Dicumarol results in decreased activity of NQO1 protein]; Dicumarol inhibits the reaction [[arsenite results in increased expression of NQO1 protein] which results in increased susceptibility to Mitomycin]; Dicumarol inhibits the reaction [NQO1 protein results in decreased susceptibility to arsenite]; Dicumarol inhibits the reaction [NQO1 protein results in increased metabolism of Mitomycin]; Dicumarol inhibits the reaction [NQO1 protein results in increased reduction of 2,6-Dichloroindophenol]; Dicumarol inhibits the reaction [TP53 protein binds to NQO1 protein]; NQO1 protein inhibits the reaction [Dicumarol results in decreased activity of MAPK10 protein] [Dicumarol results in decreased activity of NQO1 protein] which results in decreased activity of diaziquone; Dicumarol results in decreased activity of NQO1 protein Dicumarol results in decreased expression of NQO1 protein [Dicumarol results in decreased activity of NQO1 protein] which results in decreased reduction of Chromium; Dicumarol inhibits the reaction [Benzo(a)pyrene results in increased activity of NQO1 protein]; Dicumarol inhibits the reaction [NQO1 protein inhibits the reaction [Vitamin K 3 results in increased chemical synthesis of Hydrogen Peroxide]]; Dicumarol inhibits the reaction [Progesterone results in increased activity of NQO1 protein]; Dicumarol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein] [Dicumarol results in decreased activity of NQO1 protein] which results in decreased abundance of aristolactam I; [Dicumarol results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I; [Dicumarol results in decreased activity of NQO1 protein] which results in increased abundance of aristolochic acid I metabolite NQO1 protein affects the susceptibility to Dicumarol |
CTD |
PMID:1379126 PMID:1701346 PMID:2113030 PMID:8572925 PMID:10092053 PMID:10531305 PMID:11154737 PMID:14634213 PMID:15655414 PMID:15805261 PMID:16494910 PMID:17669387 PMID:17979524 PMID:19497421 PMID:21613233 PMID:21742781 PMID:21947872 PMID:27558805 PMID:29281794 PMID:33938965 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation |
ISO |
Dicumarol results in increased phosphorylation of RB1 protein |
CTD |
PMID:15896341 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rb1cc1 |
RB1-inducible coiled-coil 1 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [RB1CC1 protein results in increased expression of CDKN1A protein]; Dicumarol inhibits the reaction [RB1CC1 protein results in increased expression of TP53 protein]; Dicumarol inhibits the reaction [RB1CC1 protein results in increased stability of TP53 protein] |
CTD |
PMID:16061648 |
|
NCBI chr 5:13,161,648...13,225,560
Ensembl chr 5:13,161,648...13,225,560
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein]; Dicumarol inhibits the reaction [TNF protein affects the localization of RELA protein]; Dicumarol inhibits the reaction [TNF protein results in increased activity of RELA protein] |
CTD |
PMID:10531305 PMID:17669387 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; Dicumarol inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:15142038 |
|
NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
[Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:11299314 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases response to substance multiple interactions |
ISO EXP |
SOD2 protein results in decreased susceptibility to Dicumarol [Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD2 mRNA |
CTD |
PMID:11299314 PMID:17040906 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [TNF protein affects the localization of RELA protein]; Dicumarol inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Dicumarol inhibits the reaction [TNF protein results in increased activity of RELA protein]; Dicumarol inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; Dicumarol inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; Dicumarol inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; Dicumarol inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; Dicumarol inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; hydroquinone inhibits the reaction [Dicumarol inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]] |
CTD |
PMID:10531305 PMID:17669387 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression increases degradation |
ISO |
Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form]; Dicumarol inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein]; Dicumarol inhibits the reaction [IL1B protein results in increased expression of TP53 protein]; Dicumarol inhibits the reaction [RB1CC1 protein results in increased expression of TP53 protein]; Dicumarol inhibits the reaction [RB1CC1 protein results in increased stability of TP53 protein]; Dicumarol inhibits the reaction [TP53 protein binds to NQO1 protein] Dicumarol results in decreased expression of TP53 protein Dicumarol results in increased degradation of TP53 protein |
CTD |
PMID:14634213 PMID:16061648 PMID:17959154 PMID:22692362 PMID:26630137 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [TRAF2 protein results in increased activity of MAPK10 protein] |
CTD |
PMID:10531305 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
decreases activity multiple interactions |
ISO |
Dicumarol results in decreased activity of VKORC1 protein Dicumarol inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1] |
CTD |
PMID:29581108 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
multiple interactions decreases activity |
ISO |
Dicumarol inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] Dicumarol results in decreased activity of VKORC1L1 protein |
CTD |
PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
esculetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of AGTR1A mRNA]; esculetin inhibits the reaction [Dietary Fats results in increased expression of AGTR1A mRNA] |
CTD |
PMID:28946194 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
esculetin inhibits the reaction [Dietary Fats results in increased expression of AGTR2 mRNA]; esculetin promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of AGTR2 mRNA] |
CTD |
PMID:28946194 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
esculetin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:24995577 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
decreases expression |
ISO |
esculetin results in decreased expression of ALOX15 protein |
CTD |
PMID:30171828 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
esculetin results in increased expression of BAK1 protein |
CTD |
PMID:26388407 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression affects expression affects localization |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of BAX protein esculetin results in increased expression of BAX protein esculetin affects the expression of BAX protein esculetin affects the localization of BAX protein |
CTD |
PMID:16051289 PMID:19786087 PMID:24995577 PMID:26388407 PMID:31313495 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression decreases expression |
ISO |
esculetin affects the expression of BCL2 protein esculetin results in decreased expression of BCL2 protein |
CTD |
PMID:24995577 PMID:26388407 PMID:31313495 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[esculetin co-treated with Paclitaxel] results in decreased expression of BCL2L1 protein esculetin results in decreased expression of BCL2L1 protein |
CTD |
PMID:16051289 PMID:26388407 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[arsenic trioxide co-treated with esculetin] results in increased cleavage of BID protein |
CTD |
PMID:19428345 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
EXP |
esculetin inhibits the reaction [Streptozocin results in decreased expression of BMP6 mRNA] |
CTD |
PMID:21450970 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO |
[esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein esculetin results in increased cleavage of CASP3 protein esculetin results in increased activity of CASP3 protein |
CTD |
PMID:16051289 PMID:24995577 PMID:26388407 PMID:31313495 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases cleavage |
ISO |
esculetin results in increased cleavage of CASP7 protein |
CTD |
PMID:31313495 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:16051289 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity increases cleavage |
ISO |
esculetin results in increased activity of CASP9 protein esculetin results in increased cleavage of CASP9 protein |
CTD |
PMID:24995577 PMID:26388407 PMID:31313495 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
esculetin inhibits the reaction [Doxorubicin results in decreased expression of CAT mRNA] |
CTD |
PMID:38567888 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of CCL2 protein] |
CTD |
PMID:27769711 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP ISO |
esculetin results in decreased expression of CCND1 protein |
CTD |
PMID:21600278 PMID:31313495 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression multiple interactions |
EXP |
esculetin results in decreased expression of CDK2 protein esculetin promotes the reaction [CDKN1A protein binds to CDK2 protein]; SB 203580 inhibits the reaction [esculetin results in decreased expression of CDK2 protein] |
CTD |
PMID:21600278 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression multiple interactions |
EXP |
esculetin results in decreased expression of CDK4 protein esculetin promotes the reaction [CDKN1A protein binds to CDK4 protein]; SB 203580 inhibits the reaction [esculetin results in decreased expression of CDK4 protein] |
CTD |
PMID:21600278 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP ISO |
esculetin promotes the reaction [CDKN1A protein binds to CDK2 protein]; esculetin promotes the reaction [CDKN1A protein binds to CDK4 protein]; SB 203580 inhibits the reaction [esculetin results in increased expression of CDKN1A protein] |
CTD |
PMID:21600278 PMID:31313495 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
esculetin results in increased expression of CDKN1B protein |
CTD |
PMID:31313495 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO |
COMT protein results in increased methylation of esculetin |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[arsenic trioxide co-treated with esculetin] affects the localization of CYCS protein; [esculetin co-treated with Paclitaxel] affects the localization of CYCS protein |
CTD |
PMID:16051289 PMID:19428345 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of FAS protein |
CTD |
PMID:16051289 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of FASLG protein |
CTD |
PMID:16051289 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
esculetin promotes the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of FASN mRNA] |
CTD |
PMID:27769711 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
esculetin inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA]; esculetin inhibits the reaction [Streptozocin results in increased expression of FN1 protein] |
CTD |
PMID:21450970 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
esculetin promotes the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of G6PC1 protein] |
CTD |
PMID:27769711 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of IL6 mRNA]; esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of IL6 protein] |
CTD |
PMID:27769711 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
[esculetin co-treated with Paclitaxel] results in decreased expression of MAPK1 protein; esculetin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein esculetin results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [esculetin results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [esculetin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16051289 PMID:21600278 PMID:24995577 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[esculetin co-treated with Paclitaxel] results in decreased expression of MAPK14 protein; esculetin results in decreased phosphorylation of and results in decreased activity of MAPK14 protein |
CTD |
PMID:16051289 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
[esculetin co-treated with Paclitaxel] results in decreased expression of MAPK3 protein; esculetin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein esculetin results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [esculetin results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [esculetin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16051289 PMID:21600278 PMID:24995577 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation increases expression |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of MAPK8 protein esculetin results in increased phosphorylation of MAPK8 protein esculetin results in increased expression of MAPK8 protein |
CTD |
PMID:16051289 PMID:19786087 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases expression |
ISO |
[esculetin co-treated with Paclitaxel] results in increased expression of MAPK9 protein esculetin results in increased expression of MAPK9 protein |
CTD |
PMID:16051289 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
EXP |
esculetin inhibits the reaction [Streptozocin results in increased expression of MMP13 mRNA] |
CTD |
PMID:21450970 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of MYD88 mRNA] |
CTD |
PMID:27769711 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases localization affects localization |
ISO |
esculetin results in increased localization of NFE2L2 protein esculetin affects the localization of NFE2L2 protein |
CTD |
PMID:20933534 PMID:30171828 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
esculetin affects the localization of NFKB1 protein |
CTD |
PMID:30171828 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
esculetin promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:16212885 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
esculetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of NOS3 mRNA]; esculetin inhibits the reaction [Dietary Fats results in decreased expression of NOS3 mRNA] |
CTD |
PMID:28946194 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
esculetin results in increased expression of and results in increased activity of NQO1 protein esculetin results in increased expression of NQO1 mRNA |
CTD |
PMID:20933534 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
esculetin results in increased cleavage of PARP1 protein |
CTD |
PMID:26388407 PMID:31313495 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
esculetin inhibits the reaction [Streptozocin results in decreased expression of PPARG protein]; esculetin inhibits the reaction [Streptozocin results in increased expression of PPARG protein] esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PPARG mRNA] |
CTD |
PMID:21450970 PMID:27769711 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
esculetin affects the localization of RELA protein |
CTD |
PMID:30171828 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects expression |
ISO |
esculetin affects the expression of SOD1 protein |
CTD |
PMID:30171828 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression |
ISO |
esculetin results in decreased expression of SP1 protein |
CTD |
PMID:31313495 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
esculetin inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] |
CTD |
PMID:21450970 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TLR4 mRNA] |
CTD |
PMID:27769711 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TNF mRNA]; esculetin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TNF protein] |
CTD |
PMID:27769711 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
esculetin results in increased expression of TNFRSF10A protein |
CTD |
PMID:19786087 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tp53 |
tumor protein p53 |
increases degradation increases expression |
ISO |
esculetin results in increased degradation of TP53 protein esculetin results in increased expression of TP53 protein |
CTD |
PMID:14634213 PMID:31313495 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases metabolic processing |
EXP |
UGT2B15 protein results in increased metabolism of esculetin |
CTD |
PMID:7574722 |
|
NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589
|
|
G |
Usp16 |
ubiquitin specific peptidase 16 |
multiple interactions |
EXP |
esculetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of USP16 mRNA]; esculetin inhibits the reaction [Dietary Fats results in increased expression of USP16 mRNA] |
CTD |
PMID:28946194 |
|
NCBI chr11:26,681,359...26,711,313
Ensembl chr11:26,681,414...26,710,539
|
|
G |
Usp22 |
ubiquitin specific peptidase 22 |
multiple interactions |
EXP |
esculetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of USP22 mRNA]; esculetin inhibits the reaction [Dietary Fats results in increased expression of USP22 mRNA] |
CTD |
PMID:28946194 |
|
NCBI chr10:45,828,619...45,855,468
Ensembl chr10:45,828,622...45,855,497
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
esculetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of VCAM1 mRNA]; esculetin inhibits the reaction [Dietary Fats results in increased expression of VCAM1 mRNA] |
CTD |
PMID:28946194 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
F10 |
coagulation factor X |
multiple interactions decreases expression |
EXP |
Vitamin K 3 inhibits the reaction [Ethyl Biscoumacetate results in decreased expression of F10 protein] |
CTD |
PMID:6768192 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
fraxetin inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein] fraxetin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:34553399 PMID:37867445 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression increases expression |
ISO |
fraxetin results in decreased expression of BAX protein fraxetin results in increased expression of BAX mRNA; fraxetin results in increased expression of BAX protein Fraxetin increases expression of BAX protein in colorectum |
CTD RGD |
PMID:15996779 PMID:37867445 PMID:32504672 |
RGD:125097526 |
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Fraxetin decreases expression of BCL2 protein in colorectum fraxetin results in decreased expression of BCL2 mRNA; fraxetin results in decreased expression of BCL2 protein |
CTD RGD |
PMID:37867445 PMID:32504672 |
RGD:125097526 |
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
decreases activity increases cleavage |
ISO |
fraxetin results in decreased activity of CASP3 protein fraxetin results in increased cleavage of CASP3 protein |
CTD |
PMID:15996779 PMID:37867445 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases activity |
ISO |
fraxetin results in decreased activity of CASP9 protein |
CTD |
PMID:15996779 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
fraxetin inhibits the reaction [Rotenone results in increased expression of and results in increased activity of CAT protein] |
CTD |
PMID:15904944 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Fraxetin decreases expression of CCNA2 protein in colorectum |
RGD |
PMID:32504672 |
RGD:125097526 |
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Fraxetin decreases expression of CCNE1 protein in colorectum |
RGD |
PMID:32504672 |
RGD:125097526 |
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Fraxetin decreases expression of CDK2 protein in colorectum |
RGD |
PMID:32504672 |
RGD:125097526 |
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
fraxetin affects the localization of CYCS protein |
CTD |
PMID:15996779 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
fraxetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA] |
CTD |
PMID:30496664 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
Fraxetin decreases phosphorylation of JAK2 protein in colorectum |
RGD |
PMID:32504672 |
RGD:125097526 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases phosphorylation |
ISO |
fraxetin results in decreased phosphorylation of MAPK8 protein |
CTD |
PMID:37867445 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
fraxetin results in decreased expression of MKI67 protein |
CTD |
PMID:37867445 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
fraxetin results in increased cleavage of PARP1 protein |
CTD |
PMID:37867445 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
decreases expression |
ISO |
Fraxetin decreases expression of SKP2 mRNA and protein in colorectum |
RGD |
PMID:32504672 |
RGD:125097526 |
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
fraxetin inhibits the reaction [Rotenone results in increased expression of and results in increased activity of SOD2 protein] |
CTD |
PMID:15904944 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
Fraxetin decreases phosphorylation of STAT3 protein in colorectum |
RGD |
PMID:32504672 |
RGD:125097526 |
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
fraxetin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA] |
CTD |
PMID:30496664 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases activity |
EXP ISO |
[Novobiocin results in decreased activity of ABCG2 protein] which results in decreased secretion of Rosuvastatin Calcium [Novobiocin results in decreased activity of ABCG2 protein] which results in decreased export of Mitoxantrone; Novobiocin inhibits the reaction [5-Methoxypsoralen results in decreased activity of ABCG2 protein]; Novobiocin inhibits the reaction [[5-Methoxypsoralen results in decreased activity of ABCG2 protein] which results in decreased export of and results in increased abundance of Mitoxantrone]; Novobiocin inhibits the reaction [[Methoxsalen results in decreased activity of ABCG2 protein] which results in decreased export of and results in increased abundance of Mitoxantrone]; Novobiocin inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Novobiocin inhibits the reaction [Methoxsalen results in decreased activity of ABCG2 protein] |
CTD |
PMID:19853032 PMID:29079042 PMID:32305507 PMID:35550413 PMID:38367674 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases degradation |
ISO |
Novobiocin analog results in increased degradation of AKT1 protein |
CTD |
PMID:20711301 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
ISO |
Novobiocin results in increased expression of CD38 mRNA; Novobiocin results in increased expression of CD38 protein |
CTD |
PMID:11853877 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Novobiocin results in decreased expression of CDH2 protein |
CTD |
PMID:11853877 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases activity |
ISO |
Novobiocin results in increased activity of GGT1 protein |
CTD |
PMID:1739614 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
|
G |
F10 |
coagulation factor X |
decreases activity |
EXP |
Phenprocoumon results in decreased activity of F10 protein |
CTD |
PMID:3490277 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases activity |
EXP |
Phenprocoumon results in decreased activity of F2 protein |
CTD |
PMID:3490277 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
decreases activity |
EXP |
Phenprocoumon results in decreased activity of F5 protein |
CTD |
PMID:3490277 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
F7 |
coagulation factor VII |
decreases activity |
EXP |
Phenprocoumon results in decreased activity of F7 protein |
CTD |
PMID:3490277 |
|
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
|
|
G |
F9 |
coagulation factor IX |
decreases activity |
EXP |
Phenprocoumon results in decreased activity of F9 protein |
CTD |
PMID:3490277 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Ggcx |
gamma-glutamyl carboxylase |
increases activity |
EXP |
Phenprocoumon results in increased activity of GGCX protein |
CTD |
PMID:3490277 |
|
NCBI chr 4:104,469,737...104,485,631
Ensembl chr 4:104,469,765...104,487,063
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
Phenprocoumon results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
affects response to substance decreases activity multiple interactions decreases response to substance |
ISO |
VKORC1 gene polymorphism affects the susceptibility to Phenprocoumon; VKORC1 intron SNP affects the susceptibility to Phenprocoumon Phenprocoumon results in decreased activity of VKORC1 protein Phenprocoumon inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1] VKORC1 protein polymorphism results in decreased susceptibility to Phenprocoumon |
CTD |
PMID:15536456 PMID:16201835 PMID:17036862 PMID:18698879 PMID:29581108 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
decreases activity multiple interactions |
ISO |
Phenprocoumon results in decreased activity of VKORC1L1 protein Phenprocoumon inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] |
CTD |
PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
scoparone affects the reaction [[Dietary Fats co-treated with Dietary Sugars co-treated with Diethylnitrosamine] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:37436232 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Dietary Fats co-treated with Dietary Sugars co-treated with Diethylnitrosamine] results in decreased expression of ALB protein] |
CTD |
PMID:37436232 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
scoparone results in increased expression of BAX protein |
CTD |
PMID:37449671 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
scoparone results in decreased expression of BCL2 protein |
CTD |
PMID:37449671 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
scoparone results in increased cleavage of CASP3 protein |
CTD |
PMID:37449671 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
scoparone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CCL2 mRNA]; scoparone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of CCL2 protein] scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of CCL2 mRNA]]; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of CCL2 protein]] |
CTD |
PMID:16376386 PMID:37436232 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
scoparone results in decreased expression of CDC42 mRNA |
CTD |
PMID:37449671 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Dct |
dopachrome tautomerase |
increases expression |
ISO |
scoparone results in increased expression of DCT mRNA |
CTD |
PMID:17049123 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Dietary Sugars co-treated with Dietary Fats co-treated with scoparone] results in increased expression of GPT protein; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Sugars co-treated with Dietary Fats] results in increased expression of GPT protein]] |
CTD |
PMID:37436232 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
scoparone affects the reaction [[Dietary Fats co-treated with Dietary Sugars co-treated with Diethylnitrosamine] results in increased metabolism of IL1B protein] |
CTD |
PMID:37436232 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of JUN protein modified form] |
CTD |
PMID:23535186 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
scoparone affects the reaction [[Dietary Fats co-treated with Dietary Sugars co-treated with Diethylnitrosamine] results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:37436232 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
scoparone results in decreased expression of MMP2 mRNA |
CTD |
PMID:37449671 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
scoparone results in decreased expression of MMP9 mRNA scoparone affects the reaction [[Dietary Fats co-treated with Dietary Sugars co-treated with Diethylnitrosamine] results in increased expression of MMP9 protein]; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of MMP9 mRNA]] |
CTD |
PMID:37436232 PMID:37449671 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myl1 |
myosin, light chain 1 |
decreases phosphorylation |
ISO |
scoparone results in decreased phosphorylation of MYL1 protein |
CTD |
PMID:37449671 |
|
NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:68,437,517...68,458,261
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
scoparone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of NFKB1 protein] |
CTD |
PMID:16376386 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
scoparone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16376386 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of NOS2 mRNA]] |
CTD |
PMID:37436232 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression increases activity |
ISO |
scoparone results in increased expression of NR1H4 mRNA scoparone results in increased activity of NR1H4 protein |
CTD |
PMID:36542898 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
scoparone results in increased cleavage of PARP1 protein |
CTD |
PMID:37449671 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pfkp |
phosphofructokinase, platelet |
decreases expression |
ISO |
scoparone results in decreased expression of PFKP mRNA |
CTD |
PMID:37449671 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:37436232 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
scoparone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of REL protein] |
CTD |
PMID:16376386 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
scoparone affects the reaction [[Dietary Fats co-treated with Dietary Sugars co-treated with Diethylnitrosamine] results in increased phosphorylation of RELA protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein]; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of RELA mRNA]]; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of RELA protein]] scoparone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; scoparone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein] |
CTD |
PMID:16376386 PMID:23535186 PMID:37436232 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
scoparone results in decreased expression of RHOA mRNA; scoparone results in decreased expression of RHOA protein |
CTD |
PMID:37449671 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
decreases expression |
ISO |
scoparone results in decreased expression of ROCK1 mRNA; scoparone results in decreased expression of ROCK1 protein |
CTD |
PMID:37449671 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Ticam1 |
TIR domain containing adaptor molecule 1 |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 9:1,102,559...1,111,023
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of TNF mRNA]]; scoparone inhibits the reaction [Diethylnitrosamine promotes the reaction [[Dietary Fats co-treated with Dietary Sugars] results in increased expression of TNF protein]] |
CTD |
PMID:23535186 PMID:37436232 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [scoparone results in increased expression of TYR protein]; scoparone results in increased expression of and results in increased activity of TYR protein scoparone results in increased expression of TYR mRNA |
CTD |
PMID:17049123 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases expression |
ISO |
scoparone results in increased expression of TYRP1 mRNA |
CTD |
PMID:17049123 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of ACAA1A mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased phosphorylation of ACACA protein] |
CTD |
PMID:26115886 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of ACSL1 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of ADIPOQ mRNA]; Scopoletin inhibits the reaction [Ethanol results in decreased expression of ADIPOQ protein] |
CTD |
PMID:26115886 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor2 |
adiponectin receptor 2 |
multiple interactions increases expression |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of ADIPOR2 mRNA]; Scopoletin inhibits the reaction [Ethanol results in decreased expression of ADIPOR2 protein] scopoletin increases expression of adipor2 mRNA and protein in epididymal white adipose tissue of alcohol fed rats |
CTD RGD |
PMID:26115886 PMID:26115886 |
RGD:25330099 |
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
EXP |
Scopoletin results in decreased expression of ATF4 mRNA |
CTD |
PMID:34979142 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glucose results in increased expression of BAX protein] |
CTD |
PMID:37619648 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:37619648 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Scopoletin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein] Scopoletin inhibits the reaction [Palmitic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:34979142 PMID:37619648 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glucose results in increased expression of CASP9 protein] |
CTD |
PMID:37619648 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Alcohols affects the expression of CIDEA mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glucose results in increased expression of CYCS protein] |
CTD |
PMID:37619648 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; Scopoletin inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 mRNA] |
CTD |
PMID:34979142 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of FASN mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased activity of GPT protein] |
CTD |
PMID:26115886 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
[Glycochenodeoxycholic Acid co-treated with Scopoletin] results in increased expression of HSPA5 mRNA; [Scopoletin co-treated with Palmitic Acid] results in increased expression of HSPA5 mRNA Scopoletin results in increased expression of HSPA5 mRNA |
CTD |
PMID:34979142 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of IL10 protein] |
CTD |
PMID:26115886 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA]; Scopoletin inhibits the reaction [Ethanol results in increased expression of IL6 protein] |
CTD |
PMID:26115886 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased phosphorylation of LIPE protein] |
CTD |
PMID:26115886 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; Scopoletin inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34979142 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; Scopoletin inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34979142 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glucose results in increased phosphorylation of MAPK8 protein]; Scopoletin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK8 protein]; Scopoletin inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:34979142 PMID:37619648 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of MYD88 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Glucose results in decreased expression of PARP1 protein] |
CTD |
PMID:37619648 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of PNPLA2 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of SREBF1 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Ticam1 |
TIR domain containing adaptor molecule 1 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of TICAM1 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr 9:1,102,559...1,111,023
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of TLR4 mRNA] |
CTD |
PMID:26115886 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Scopoletin inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; Scopoletin inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:26115886 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of Scopoletin |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Scopoletin |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases glucuronidation |
ISO |
UGT1A6 protein results in increased glucuronidation of Scopoletin |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of Scopoletin |
CTD |
PMID:15044611 PMID:15802387 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases metabolic processing |
EXP |
UGT2B15 protein results in increased metabolism of Scopoletin |
CTD |
PMID:7574722 |
|
NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589
|
|
G |
Xpc |
XPC complex subunit, DNA damage recognition and repair factor |
affects response to substance |
ISO |
XPC protein affects the susceptibility to Scopoletin |
CTD |
PMID:22280988 |
|
NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010
|
|
|
G |
Ide |
insulin degrading enzyme |
multiple interactions |
ISO |
scopolin binds to and affects the activity of IDE protein |
CTD |
PMID:23146021 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Urod |
uroporphyrinogen decarboxylase |
multiple interactions |
ISO |
scopolin binds to and affects the activity of UROD protein |
CTD |
PMID:23209648 |
|
NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
7-hydroxycoumarin inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:24661945 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions increases expression |
ISO |
7-hydroxycoumarin inhibits the reaction [AKR1C3 mutant form results in increased susceptibility to 4-hydroxy-2-nonenal]; 7-hydroxycoumarin inhibits the reaction [AKR1C3 mutant form results in increased susceptibility to Hydrogen Peroxide] 7-hydroxycoumarin results in increased expression of AKR1C3 mRNA; 7-hydroxycoumarin results in increased expression of AKR1C3 protein |
CTD |
PMID:22964423 PMID:28263721 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions increases expression |
ISO |
7-hydroxycoumarin affects the reaction [AKR7A2 mutant form results in increased susceptibility to 4-hydroxy-2-nonenal] 7-hydroxycoumarin results in increased expression of AKR7A2 mRNA; 7-hydroxycoumarin results in increased expression of AKR7A2 protein |
CTD |
PMID:22964423 PMID:28263721 PMID:30849339 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases expression |
ISO |
7-hydroxycoumarin results in increased expression of AKR7A3 mRNA |
CTD |
PMID:28263721 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
EXP |
7-hydroxycoumarin results in decreased expression of ATF4 mRNA |
CTD |
PMID:34979142 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
7-hydroxycoumarin results in increased expression of BAX protein 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [7-hydroxycoumarin inhibits the reaction [Glycerol results in increased expression of BAX protein]]; 7-hydroxycoumarin inhibits the reaction [Glycerol results in increased expression of BAX protein] |
CTD |
PMID:15964220 PMID:34409680 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
7-hydroxycoumarin results in decreased expression of BCL2 protein 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [7-hydroxycoumarin inhibits the reaction [Glycerol results in decreased expression of BCL2 protein]]; 7-hydroxycoumarin inhibits the reaction [Glycerol results in decreased expression of BCL2 protein] |
CTD |
PMID:15964220 PMID:34409680 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
EXP ISO |
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein] 7-hydroxycoumarin inhibits the reaction [Palmitic Acid results in increased activity of CASP3 protein] 7-hydroxycoumarin results in increased activity of CASP3 protein |
CTD |
PMID:34979142 PMID:37704181 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
7-hydroxycoumarin inhibits the reaction [Dietary Fats results in decreased activity of CAT protein] |
CTD |
PMID:24661945 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
7-hydroxycoumarin results in decreased expression of CCND1 protein |
CTD |
PMID:11679177 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression multiple interactions |
EXP |
7-hydroxycoumarin results in increased expression of CREB1 mRNA 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of CREB1 mRNA] |
CTD |
PMID:33522649 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cygb |
cytoglobin |
multiple interactions increases expression |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of CYGB protein] 7-hydroxycoumarin results in increased expression of CYGB protein |
CTD |
PMID:33522649 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP1A2 protein results in increased metabolism of coumarin] which results in increased abundance of 7-hydroxycoumarin |
CTD |
PMID:34334558 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
7-hydroxycoumarin inhibits the reaction [Dietary Fats results in increased activity of CYP2E1 protein] |
CTD |
PMID:24661945 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA] |
CTD |
PMID:34979142 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in increased expression of FOXO3 mRNA] |
CTD |
PMID:33522649 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in increased expression of HAVCR1 protein] |
CTD |
PMID:33522649 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Isoproterenol results in increased activity of HMGCR protein] |
CTD |
PMID:26995004 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
[7-hydroxycoumarin co-treated with Palmitic Acid] results in increased expression of HSPA5 mRNA 7-hydroxycoumarin results in increased expression of HSPA5 mRNA |
CTD |
PMID:34979142 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in increased expression of IKBKB protein] |
CTD |
PMID:33522649 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:33522649 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] |
CTD |
PMID:36650709 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:36650709 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of JAK2 mRNA]; 7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of JAK2 protein] |
CTD |
PMID:36650709 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; 7-hydroxycoumarin inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34979142 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; 7-hydroxycoumarin inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34979142 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MAPK8 protein]; 7-hydroxycoumarin inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:34979142 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases oxidation |
ISO |
[4-aminobenzhydrazide results in decreased activity of MPO protein] which affects the susceptibility to 7-hydroxycoumarin MPO protein results in increased oxidation of 7-hydroxycoumarin |
CTD |
PMID:23994743 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO EXP |
7-hydroxycoumarin results in increased expression of and affects the localization of NFE2L2 protein 7-hydroxycoumarin results in increased expression of NFE2L2 mRNA; 7-hydroxycoumarin results in increased expression of NFE2L2 protein 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA]; 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:28263721 PMID:33522649 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression multiple interactions |
EXP |
7-hydroxycoumarin results in decreased expression of NFKBIA protein 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of NFKBIA protein] |
CTD |
PMID:33522649 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of PPARG mRNA] 7-hydroxycoumarin results in increased expression of PPARG mRNA |
CTD |
PMID:33522649 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in increased expression of RELA protein] |
CTD |
PMID:33522649 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP |
7-hydroxycoumarin results in increased expression of SIRT1 mRNA 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of SIRT1 mRNA] |
CTD |
PMID:33522649 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of STAT3 mRNA]; 7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of STAT3 protein] |
CTD |
PMID:36650709 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO EXP |
SULT1A1 protein results in increased sulfation of 7-hydroxycoumarin |
CTD |
PMID:11181495 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of TGFB1 mRNA]; 7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] |
CTD |
PMID:36650709 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
7-hydroxycoumarin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; 7-hydroxycoumarin inhibits the reaction [Streptozocin results in increased expression of TNF protein] |
CTD |
PMID:33522649 PMID:36650709 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
affects metabolic processing increases metabolic processing |
EXP |
UGT1A6 gene polymorphism affects the metabolism of 7-hydroxycoumarin UGT1A6 protein results in increased metabolism of 7-hydroxycoumarin |
CTD |
PMID:9429234 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a7c |
UDP glucuronosyltransferase 1 family, polypeptide A7C |
increases glucuronidation |
EXP |
UGT1A7 protein results in increased glucuronidation of 7-hydroxycoumarin |
CTD |
PMID:15502008 |
|
NCBI chr 9:88,739,577...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a8 |
UDP glucuronosyltransferase family 1 member A8 |
increases glucuronidation |
EXP |
UGT1A8 protein results in increased glucuronidation of 7-hydroxycoumarin |
CTD |
PMID:15502008 |
|
NCBI chr 9:88,727,094...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 7-hydroxycoumarin |
CTD |
PMID:15044611 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases metabolic processing |
EXP |
UGT2B15 protein results in increased metabolism of 7-hydroxycoumarin |
CTD |
PMID:7574722 |
|
NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance increases expression |
ISO |
ABCB1 polymorphism affects the susceptibility to Warfarin Warfarin results in increased expression of ABCB1A mRNA |
CTD |
PMID:24092646 PMID:25312789 PMID:27397090 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions increases response to substance |
ISO |
[Magnesium deficiency co-treated with Phosphates] promotes the reaction [ABCC6 gene mutant form results in increased susceptibility to Warfarin] |
CTD |
PMID:23415960 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects response to substance |
ISO |
ABCG2 SNP affects the susceptibility to Warfarin |
CTD |
PMID:25300812 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of ACTA2 mRNA |
CTD |
PMID:23117658 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
increases expression decreases expression |
ISO |
Warfarin results in increased expression of ACTB mRNA Warfarin results in decreased expression of ACTB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
ISO |
Warfarin results in increased expression of ACTR3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
EXP |
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of ADIPOQ protein] Warfarin results in increased expression of ADIPOQ protein |
CTD |
PMID:27488359 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 mRNA]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1 protein] |
CTD |
PMID:36162953 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO |
Warfarin results in decreased expression of AHCY mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP inhibits the reaction [[Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein]; [Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein; [Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:22659116 PMID:27212383 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions affects binding decreases expression |
ISO EXP |
[Warfarin binds to ALB protein] inhibits the reaction [copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) binds to ALB protein]; [Warfarin binds to ALB protein] inhibits the reaction [copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex binds to ALB protein]; Aspirin inhibits the reaction [Warfarin binds to ALB protein]; prodan inhibits the reaction [Warfarin binds to ALB protein]; Pyruvaldehyde inhibits the reaction [Warfarin binds to ALB protein] Warfarin results in decreased expression of ALB protein |
CTD |
PMID:10506189 PMID:12044178 PMID:18937368 PMID:19596536 PMID:20934417 PMID:20956006 PMID:22342526 PMID:25499135 More...
|
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
ISO |
Warfarin results in increased expression of ALOX5AP mRNA |
CTD |
PMID:16698924 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
Warfarin results in decreased expression of ANXA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Warfarin results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoa1 |
apolipoprotein A1 |
affects response to substance |
ISO |
APOA1 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:32282500 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
affects response to substance |
ISO |
APOB gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:31186542 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
increases response to substance affects response to substance |
ISO |
APOE gene mutant form results in increased susceptibility to Warfarin APOE gene mutant form affects the susceptibility to Warfarin; APOE gene polymorphism affects the susceptibility to Warfarin; APOE gene SNP affects the susceptibility to Warfarin; APOE polymorphism affects the susceptibility to Warfarin; APOE protein affects the susceptibility to Warfarin; APOE SNP affects the susceptibility to Warfarin |
CTD |
PMID:15952022 PMID:16847429 PMID:17048007 PMID:17325732 PMID:21228733 PMID:23415960 PMID:25312789 PMID:28079798 PMID:31854268 More...
|
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Warfarin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arsl |
arylsulfatase L |
decreases activity |
ISO |
Warfarin results in decreased activity of ARSL protein |
CTD |
PMID:7720070 |
|
NCBI chr 2:119,038,803...119,047,579
Ensembl chr 2:119,038,921...119,046,846
|
|
G |
Asph |
aspartate-beta-hydroxylase |
affects response to substance |
ISO |
ASPH gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488176 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Axin2 |
axin 2 |
multiple interactions increases expression |
EXP |
[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of AXIN2 mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Axl |
Axl receptor tyrosine kinase |
multiple interactions decreases phosphorylation increases response to substance decreases expression |
EXP ISO |
[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of AXL protein] Warfarin results in decreased phosphorylation of AXL protein AXL protein results in increased susceptibility to Warfarin AXL protein promotes the reaction [Warfarin results in increased susceptibility to Gemcitabine]; Vitamin K inhibits the reaction [Warfarin results in decreased expression of AXL protein modified form]; Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein] Warfarin results in decreased expression of AXL protein; Warfarin results in decreased expression of AXL protein modified form |
CTD |
PMID:15123721 PMID:26206560 PMID:27212383 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein] |
CTD |
PMID:27212383 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions increases expression |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [menaquinone 7 results in increased carboxylation of BGLAP protein]; Warfarin inhibits the reaction [menatetrenone results in increased carboxylation of BGLAP protein]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [Vitamin K 1 results in increased carboxylation of BGLAP protein] Warfarin results in increased expression of BGLAP mRNA; Warfarin results in increased expression of BGLAP protein modified form [Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of BGLAP protein modified form] |
CTD |
PMID:21910061 PMID:23117658 PMID:23223575 PMID:27488359 PMID:31173816 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein] |
CTD |
PMID:21910061 PMID:27412937 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
C1qbp |
complement C1q binding protein |
increases expression |
ISO |
Warfarin results in increased expression of C1QBP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Warfarin results in increased expression of CALR mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calu |
calumenin |
decreases response to substance affects response to substance |
EXP ISO |
CALU protein results in decreased susceptibility to Warfarin CALU gene SNP affects the susceptibility to Warfarin; CALU polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:11641264 PMID:20200517 PMID:27632229 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Casp3 |
caspase 3 |
decreases expression increases expression multiple interactions |
ISO EXP |
Warfarin results in decreased expression of CASP3 mRNA Warfarin results in increased expression of CASP3 protein modified form [Warfarin co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein Warfarin results in increased expression of CASP3 mRNA |
CTD |
PMID:19815060 PMID:20493250 PMID:23990204 PMID:26206560 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity |
EXP |
Warfarin results in increased activity of CAT protein |
CTD |
PMID:22342526 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
EXP |
Warfarin results in increased expression of CCND1 mRNA [Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of CCND1 mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
increases expression |
ISO |
Warfarin results in increased expression of CCT5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
increases expression |
ISO |
Warfarin results in increased expression of CCT6A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
ISO |
Warfarin results in decreased expression of CCT8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Warfarin results in decreased expression of CDC42 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Warfarin results in increased expression of CDH1 protein |
CTD |
PMID:26206560 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of CLIC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of CNN1 mRNA |
CTD |
PMID:23117658 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA] [Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of COL1A1 mRNA] |
CTD |
PMID:21910061 PMID:23117658 PMID:23223575 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cox15 |
cytochrome c oxidase assembly homolog COX15 |
affects response to substance |
ISO |
COX15 gene affects the susceptibility to Warfarin |
CTD |
PMID:28686080 |
|
NCBI chr 1:242,605,588...242,622,279
Ensembl chr 1:242,605,588...242,622,261
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
increases expression |
ISO |
Warfarin results in increased expression of COX5A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
increases expression |
ISO |
Warfarin results in increased expression of CRK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions affects response to substance |
ISO EXP |
Warfarin results in decreased expression of and affects the localization of CTNNB1 protein CTNNB1 protein affects the susceptibility to Warfarin Quercetin inhibits the reaction [Warfarin results in increased expression of and affects the localization of CTNNB1 protein]; Warfarin results in increased expression of and affects the localization of CTNNB1 protein |
CTD |
PMID:23117658 PMID:23223575 PMID:26206560 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing affects response to substance |
ISO |
CYP1A2 protein affects the metabolism of Warfarin CYP1A2 SNP affects the susceptibility to Warfarin |
CTD |
PMID:14676821 PMID:15280511 PMID:28079798 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases metabolic processing affects response to substance |
EXP ISO |
CYP2C11 protein results in increased metabolism of Warfarin CYP2C18 gene polymorphism affects the susceptibility to Warfarin; CYP2C18 protein affects the susceptibility to Warfarin |
CTD |
PMID:19752777 PMID:30724651 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
affects response to substance decreases activity affects metabolic processing multiple interactions |
ISO |
CYP2C19 gene polymorphism affects the susceptibility to Warfarin; CYP2C19 polymorphism affects the susceptibility to Warfarin; CYP2C19 protein affects the susceptibility to Warfarin Warfarin results in decreased activity of CYP2C29 protein CYP2C19 protein affects the metabolism of Warfarin CYP2C19 gene polymorphism affects the metabolism of and affects the susceptibility to Warfarin; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin] |
CTD |
PMID:18420780 PMID:18520598 PMID:19752777 PMID:25652102 PMID:27356304 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects response to substance |
ISO |
CYP2C8 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:34382722 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Warfarin results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression affects hydroxylation multiple interactions decreases expression affects metabolic processing affects response to substance decreases activity |
EXP ISO |
Warfarin results in increased expression of CYP3A2 mRNA CYP3A4 protein affects the hydroxylation of Warfarin [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Warfarin results in decreased expression of CYP3A4 mRNA CYP3A4 protein affects the metabolism of Warfarin CYP3A4 SNP affects the susceptibility to Warfarin Warfarin results in decreased activity of CYP3A4 protein CYP3A2 mRNA affects the susceptibility to Warfarin |
CTD |
PMID:2271712 PMID:11531004 PMID:15280511 PMID:16035367 PMID:18420780 PMID:20735727 PMID:28079798 PMID:30963258 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance |
ISO |
CYP3A5 gene polymorphism affects the susceptibility to Warfarin; CYP3A5 polymorphism affects the susceptibility to Warfarin; CYP3A5 protein affects the susceptibility to Warfarin |
CTD |
PMID:19752777 PMID:34382722 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dctn2 |
dynactin subunit 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of DCTN2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
affects response to substance |
ISO |
DDHD1 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488176 |
|
NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
|
|
G |
Ddt |
D-dopachrome tautomerase |
decreases expression |
ISO |
Warfarin results in decreased expression of DDT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Warfarin results in decreased expression of DLST mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
increases expression |
ISO |
Warfarin results in increased expression of DOCK7 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
ISO |
Warfarin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
decreases expression |
ISO |
Warfarin results in decreased expression of DSTN mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of EEF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
decreases expression |
ISO |
Warfarin results in decreased expression of EIF3I mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
|
|
G |
Emcn |
endomucin |
decreases expression |
ISO |
Warfarin results in decreased expression of EMCN protein |
CTD |
PMID:26206560 |
|
NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
increases expression |
EXP |
Warfarin results in increased expression of ENPP1 mRNA; Warfarin results in increased expression of ENPP1 protein |
CTD |
PMID:22659116 |
|
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
|
|
G |
Epha7 |
Eph receptor A7 |
affects response to substance |
ISO |
EPHA7 promoter SNP affects the susceptibility to Warfarin |
CTD |
PMID:30357299 |
|
NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases response to substance affects response to substance |
ISO |
EPHX1 protein results in increased susceptibility to Warfarin EPHX1 gene polymorphism affects the susceptibility to Warfarin; EPHX1 gene SNP affects the susceptibility to Warfarin; EPHX1 intron SNP affects the susceptibility to Warfarin; EPHX1 polymorphism affects the susceptibility to Warfarin; EPHX1 SNP affects the susceptibility to Warfarin |
CTD |
PMID:15900282 PMID:17496169 PMID:20842355 PMID:21192345 PMID:24092646 PMID:27632229 PMID:28079798 More...
|
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Warfarin results in decreased expression of ERP29 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
F10 |
coagulation factor X |
decreases activity |
EXP |
Warfarin results in decreased activity of F10 protein |
CTD |
PMID:3490277 PMID:20371969 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions decreases activity decreases expression affects response to substance |
ISO EXP |
Fenofibrate promotes the reaction [Warfarin results in decreased expression of F2 protein] Warfarin results in decreased activity of F2 protein F2 gene polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:3490277 PMID:9681093 PMID:14656880 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
affects response to substance decreases activity |
ISO EXP |
F5 gene polymorphism affects the susceptibility to Warfarin; F5 protein affects the susceptibility to Warfarin Warfarin results in decreased activity of F5 protein |
CTD |
PMID:3490277 PMID:19752777 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
F7 |
coagulation factor VII |
affects response to substance decreases activity multiple interactions decreases expression |
ISO EXP |
F7 gene mutant form affects the susceptibility to Warfarin; F7 gene polymorphism affects the susceptibility to Warfarin Warfarin results in decreased activity of F7 protein Fenofibrate promotes the reaction [Warfarin results in decreased expression of F7 protein] |
CTD |
PMID:3490277 PMID:9681093 PMID:14656880 PMID:20371969 PMID:20885134 |
|
NCBI chr16:76,489,775...76,500,636
Ensembl chr16:76,489,717...76,500,610
|
|
G |
F9 |
coagulation factor IX |
decreases activity increases response to substance |
EXP ISO |
Warfarin results in decreased activity of F9 protein F9 gene alternative form results in increased susceptibility to Warfarin |
CTD |
PMID:3490277 PMID:29450643 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
EXP |
Warfarin inhibits the reaction [3-(p-azidobenzyl)-4-hydroxycoumarin binds to Fabp1 protein] |
RGD |
PMID:1939124 |
RGD:1626448 |
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
affects response to substance |
ISO |
FGF5 gene affects the susceptibility to Warfarin |
CTD |
PMID:28686080 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fpgs |
folylpolyglutamate synthase |
affects response to substance |
ISO |
FPGS gene polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:25079360 |
|
NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of FSCN1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
increases expression |
ISO |
Warfarin results in increased expression of G3BP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
Gal3st1 |
galactose-3-O-sulfotransferase 1 |
increases expression |
ISO |
Warfarin results in increased expression of GAL3ST1 mRNA |
CTD |
PMID:27397090 |
|
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
|
|
G |
Gale |
UDP-galactose-4-epimerase |
decreases expression |
ISO |
Warfarin results in decreased expression of GALE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gas6 |
growth arrest specific 6 |
decreases expression multiple interactions decreases carboxylation |
EXP ISO |
Warfarin results in decreased expression of GAS6 protein Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein] Warfarin results in decreased carboxylation of GAS6 protein [Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein]; Warfarin results in decreased activity of and results in decreased carboxylation of GAS6 protein |
CTD |
PMID:9163328 PMID:19564549 PMID:26206560 PMID:27212383 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
Gata4 |
GATA binding protein 4 |
affects response to substance |
ISO |
GATA4 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:31190750 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gata6 |
GATA binding protein 6 |
affects response to substance |
ISO |
GATA6 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:31190750 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
increases expression |
ISO |
Warfarin results in increased expression of GDI2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
Warfarin results in increased expression of GFAP mRNA; Warfarin results in increased expression of GFAP protein |
CTD |
PMID:27397090 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggcx |
gamma-glutamyl carboxylase |
affects response to substance increases activity increases response to substance decreases response to substance |
ISO EXP |
GGCX gene polymorphism affects the susceptibility to Warfarin; GGCX gene SNP affects the susceptibility to Warfarin; GGCX polymorphism affects the susceptibility to Warfarin Warfarin results in increased activity of GGCX protein GGCX protein results in increased susceptibility to Warfarin GGCX gene polymorphism results in decreased susceptibility to Warfarin |
CTD |
PMID:3490277 PMID:16676068 PMID:17049586 PMID:17496169 PMID:17764537 PMID:21195460 PMID:21326313 PMID:22161100 PMID:25042728 PMID:27632229 More...
|
|
NCBI chr 4:104,469,737...104,485,631
Ensembl chr 4:104,469,765...104,487,063
|
|
G |
Gmps |
guanine monophosphate synthase |
increases expression |
ISO |
Warfarin results in increased expression of GMPS mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875
|
|
G |
Gprc6a |
G protein-coupled receptor, class C, group 6, member A |
multiple interactions |
EXP |
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GPRC6A mRNA] |
CTD |
PMID:27488359 |
|
NCBI chr20:30,922,106...30,943,412
Ensembl chr20:30,922,106...30,943,412
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:23117658 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression |
ISO |
Warfarin results in increased expression of HDAC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:36162953 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
increases expression |
ISO |
Warfarin results in increased expression of HINT1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of HMGCR mRNA] |
CTD |
PMID:27488359 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression |
EXP |
Warfarin affects the expression of HMOX1 mRNA |
CTD |
PMID:22954530 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
ISO |
Warfarin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
ISO |
Warfarin results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
increases expression |
ISO |
Warfarin results in increased expression of HNRNPF mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
increases expression decreases expression |
ISO |
Warfarin results in increased expression of HNRNPK mRNA Warfarin results in decreased expression of HNRNPK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hp |
haptoglobin |
increases expression |
EXP |
Warfarin results in increased expression of HP protein |
CTD |
PMID:22342526 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
Warfarin results in increased expression of HSPA8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
Warfarin results in increased expression of HSPD1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il12a |
interleukin 12A |
increases expression |
EXP |
Warfarin results in increased expression of IL12A mRNA |
CTD |
PMID:22342526 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
increases expression |
EXP |
Warfarin results in increased expression of IL12B mRNA |
CTD |
PMID:22342526 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
Warfarin inhibits the reaction [Vitamin K 2 results in decreased susceptibility to IL1B protein] Warfarin results in decreased expression of IL1B mRNA [Warfarin co-treated with Vitamin K] results in increased expression of IL1B mRNA |
CTD |
PMID:20460758 PMID:23117658 PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Warfarin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions decreases expression decreases secretion |
EXP ISO |
Warfarin results in increased expression of IL6 protein [Warfarin co-treated with Vitamin K] results in increased expression of IL6 mRNA Warfarin results in decreased expression of IL6 mRNA Warfarin results in decreased secretion of IL6 protein Warfarin results in decreased expression of IL6 protein |
CTD |
PMID:18772604 PMID:22342526 PMID:23117658 PMID:26742017 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
increases secretion multiple interactions |
EXP |
Warfarin results in increased secretion of INS1 protein Warfarin inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased secretion of INS1 protein] |
CTD |
PMID:27488359 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ipo5 |
importin 5 |
decreases expression |
ISO |
Warfarin results in decreased expression of IPO5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
ISO |
Warfarin results in increased expression of ISYNA1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
ISO |
Warfarin results in decreased expression of KRT18 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of LASP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
affects response to substance |
ISO |
LRP1 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:32282500 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36162953 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36162953 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgp |
matrix Gla protein |
multiple interactions decreases carboxylation |
ISO EXP |
[[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein] which results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased expression of MGP mRNA Warfarin results in decreased carboxylation of MGP protein [Quercetin co-treated with Warfarin] results in decreased carboxylation of MGP protein; [Vitamin K co-treated with Warfarin] results in increased carboxylation of MGP protein; Warfarin inhibits the reaction [Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form]; Warfarin results in decreased expression of and results in decreased secretion of MGP protein; Warfarin results in decreased expression of and results in decreased secretion of MGP protein modified form |
CTD |
PMID:21705322 PMID:23223575 PMID:23990204 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mir3582 |
microRNA 3582 |
affects response to substance |
ISO |
MIR133A2 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:26113018 |
|
NCBI chr18:1,885,063...1,885,180
Ensembl chr18:1,885,063...1,885,180
|
|
G |
Mpo |
myeloperoxidase |
increases activity |
EXP |
Warfarin results in increased activity of MPO protein |
CTD |
PMID:26742017 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myh1 |
myosin heavy chain 1 |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of MYH1 mRNA |
CTD |
PMID:23117658 |
|
NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295
|
|
G |
Myh6 |
myosin heavy chain 6 |
affects response to substance |
ISO |
MYH6 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:34515533 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
affects response to substance |
ISO |
NEDD4 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488176 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nmral1 |
NmrA like redox sensor 1 |
increases expression |
ISO |
Warfarin results in increased expression of NMRAL1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
affects response to substance |
ISO |
NQO1 gene SNP affects the susceptibility to Warfarin; NQO1 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:23215885 PMID:26257249 PMID:27581200 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions decreases expression |
ISO |
[Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA; [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Warfarin binds to and results in increased activity of NR1I2 protein Warfarin results in decreased expression of NR1I2 mRNA |
CTD |
PMID:20735727 PMID:30963258 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nucb1 |
nucleobindin 1 |
increases expression |
ISO |
Warfarin results in increased expression of NUCB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
multiple interactions |
EXP |
[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Oat |
ornithine aminotransferase |
decreases expression |
ISO |
Warfarin results in decreased expression of OAT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions affects binding increases response to substance affects response to substance |
ISO |
Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Dipyridamole inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Lidocaine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]; Progesterone inhibits the reaction [Warfarin binds to ORM1 protein alternative form] ORM1 protein results in increased susceptibility to Warfarin ORM1 gene polymorphism affects the susceptibility to Warfarin; ORM1 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:8946472 PMID:17496169 PMID:23208322 PMID:26644206 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
ISO |
Warfarin results in increased expression of PA2G4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression |
ISO |
Warfarin results in increased expression of PARP1 protein modified form |
CTD |
PMID:26206560 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
EXP |
Warfarin results in decreased expression of PDGFB mRNA; Warfarin results in decreased expression of PDGFB protein |
CTD |
PMID:11290560 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
increases expression decreases expression |
ISO |
Warfarin results in increased expression of PDIA3 mRNA Warfarin results in decreased expression of PDIA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Warfarin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
decreases expression increases expression |
ISO |
Warfarin results in decreased expression of PGAM1 mRNA Warfarin results in increased expression of PGAM1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pkm |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Warfarin results in decreased expression of PKM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plp1 |
proteolipid protein 1 |
increases expression |
ISO |
Warfarin results in increased expression of PLP1 mRNA |
CTD |
PMID:27397090 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects response to substance |
ISO |
POR gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:27488389 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Warfarin results in decreased expression of PPP1CA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
ISO |
Warfarin results in increased expression of PPP2R1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Proc |
protein C, inactivator of coagulation factors Va and VIIIa |
increases response to substance affects response to substance |
ISO |
PROC protein results in increased susceptibility to Warfarin PROC gene polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:17048007 PMID:17496169 |
|
NCBI chr18:23,764,367...23,774,816
Ensembl chr18:23,764,368...23,775,133
|
|
G |
Pros1 |
protein S |
affects response to substance |
ISO |
PROS1 gene polymorphism affects the susceptibility to Warfarin; PROS1 protein affects the susceptibility to Warfarin |
CTD |
PMID:19752777 |
|
NCBI chr11:230,597...311,288
Ensembl chr11:230,696...311,286
|
|
G |
Prss53 |
serine protease 53 |
affects response to substance |
ISO |
PRSS53 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:21590310 |
|
NCBI chr 1:182,494,944...182,501,607
Ensembl chr 1:182,494,955...182,500,115
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
decreases expression |
ISO |
Warfarin results in decreased expression of PSMA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Psma6 |
proteasome 20S subunit alpha 6 |
decreases expression |
ISO |
Warfarin results in decreased expression of PSMA6 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of PSMC2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
|
|
G |
Pth |
parathyroid hormone |
decreases activity |
ISO |
Warfarin results in decreased activity of PTH protein |
CTD |
PMID:11564701 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
decreases expression |
ISO |
Warfarin results in decreased expression of RAB1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
Warfarin results in decreased expression of RHOA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl27 |
ribosomal protein L27 |
increases expression |
ISO |
Warfarin results in increased expression of RPL27 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl9 |
ribosomal protein L9 |
increases expression |
ISO |
Warfarin results in increased expression of RPL9 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136 Ensembl chr 3:42,893,942...42,897,136
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Warfarin results in increased expression of RPLP0 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:36162953 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
ISO |
Warfarin results in increased expression of RPSA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
increases expression multiple interactions |
EXP |
Warfarin results in increased expression of RUNX1 mRNA Quercetin inhibits the reaction [Warfarin results in increased expression of RUNX1 mRNA] |
CTD |
PMID:23223575 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO EXP |
Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein; [Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:21910061 PMID:23117658 PMID:27412937 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
decreases expression |
ISO |
Warfarin results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of SAE1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Sephs1 |
selenophosphate synthetase 1 |
increases expression |
ISO |
Warfarin results in increased expression of SEPHS1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593
|
|
G |
Serpinc1 |
serpin family C member 1 |
increases expression |
ISO |
Warfarin results in increased expression of SERPINC1 protein |
CTD |
PMID:73932 |
|
NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
affects response to substance |
ISO |
SLC15A2 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:29234073 |
|
NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
affects response to substance |
ISO |
SLCO1B3 gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:29234073 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sost |
sclerostin |
affects response to substance |
ISO |
SOST affects the susceptibility to Warfarin |
CTD |
PMID:35038187 |
|
NCBI chr10:86,912,517...86,915,561
Ensembl chr10:86,911,517...86,915,561
|
|
G |
Sox5 |
SRY-box transcription factor 5 |
affects localization decreases expression |
ISO |
Warfarin affects the localization of SOX5 protein Warfarin results in decreased expression of SOX5 mRNA; Warfarin results in decreased expression of SOX5 protein |
CTD |
PMID:34520801 |
|
NCBI chr 4:176,781,375...177,736,833
Ensembl chr 4:176,785,892...177,736,852
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects localization multiple interactions |
ISO |
Warfarin affects the localization of SOX9 protein leptomycin B inhibits the reaction [Warfarin affects the localization of SOX9 protein] |
CTD |
PMID:34520801 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO EXP |
[Warfarin co-treated with Vitamin K 1] results in increased expression of SPP1 mRNA [Quercetin co-treated with Warfarin] results in increased expression of SPP1 mRNA; [Warfarin co-treated with Vitamin K] results in increased expression of SPP1 mRNA |
CTD |
PMID:23117658 PMID:23223575 PMID:23990204 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of STIP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Tagln |
transgelin |
multiple interactions |
ISO EXP |
[Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA |
CTD |
PMID:23117658 PMID:23990204 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tcf4 |
transcription factor 4 |
increases expression multiple interactions |
EXP |
Warfarin results in increased expression of TCF4 mRNA [Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA]; Quercetin inhibits the reaction [Warfarin results in increased expression of TCF4 mRNA] |
CTD |
PMID:23117658 |
|
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
|
|
G |
Tcp1 |
t-complex 1 |
increases expression |
ISO |
Warfarin results in increased expression of TCP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839
|
|
G |
Tgm2 |
transglutaminase 2 |
affects response to substance multiple interactions increases response to substance |
ISO EXP |
[TGM2 protein affects the susceptibility to Warfarin] which affects the susceptibility to Quercetin; TGM2 protein affects the susceptibility to Warfarin [Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein]; Quercetin inhibits the reaction [Warfarin results in increased activity of TGM2 protein]; Warfarin results in increased expression of and results in increased activity of TGM2 protein TGM2 protein results in increased susceptibility to Warfarin |
CTD |
PMID:23117658 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Thop1 |
thimet oligopeptidase 1 |
increases expression |
ISO |
Warfarin results in increased expression of THOP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,632,911...8,645,339
Ensembl chr 7:8,632,916...8,645,275
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases expression multiple interactions decreases secretion |
EXP |
Warfarin results in decreased expression of TNF mRNA Warfarin results in increased expression of TNF [Warfarin co-treated with Vitamin K] results in increased expression of TNF mRNA Warfarin results in decreased secretion of TNF protein |
CTD |
PMID:21565690 PMID:22342526 PMID:23117658 PMID:26742017 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases degradation increases expression |
ISO |
Warfarin results in increased degradation of TP53 protein Warfarin results in increased expression of TRP53 mRNA; Warfarin results in increased expression of TRP53 protein |
CTD |
PMID:14634213 PMID:29358327 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
ISO |
Warfarin results in increased expression of TUBA1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tuba1b |
tubulin, alpha 1B |
decreases expression increases expression |
ISO |
Warfarin results in decreased expression of TUBA1B mRNA Warfarin results in increased expression of TUBA1B mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
ISO |
Warfarin results in decreased expression of TUBB5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Warfarin results in decreased expression of TUFM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
Tyro3 |
TYRO3 protein tyrosine kinase |
decreases expression |
ISO |
Warfarin results in decreased expression of TYRO3 mRNA |
CTD |
PMID:18772604 PMID:27397090 |
|
NCBI chr 3:106,777,686...106,797,154
Ensembl chr 3:106,777,635...106,797,142
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
ISO |
Warfarin results in increased expression of U2AF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions affects response to substance increases metabolic processing |
ISO |
[UGT1A1 protein results in increased metabolism of Warfarin] which results in increased chemical synthesis of Glucuronides; [Warfarin binds to and results in decreased activity of UGT1A1 protein] which results in decreased glucuronidation of Estradiol; Warfarin binds to and results in decreased activity of UGT1A1 protein; Warfarin inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Estradiol] UGT1A1 gene SNP affects the susceptibility to Warfarin; UGT1A1 polymorphism affects the susceptibility to Warfarin |
CTD |
PMID:19408964 PMID:25312789 PMID:25393417 PMID:26223945 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions |
ISO |
[Warfarin binds to and results in increased activity of UGT1A3 protein] which results in increased glucuronidation of vorinostat; Warfarin binds to and results in increased activity of UGT1A3 protein; Warfarin promotes the reaction [UGT1A3 protein results in increased glucuronidation of vorinostat] |
CTD |
PMID:25393417 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
[Warfarin binds to and affects the activity of UGT1A9 protein] which affects the glucuronidation of Propofol; Warfarin affects the reaction [UGT1A9 protein results in increased glucuronidation of Propofol]; Warfarin binds to and affects the activity of UGT1A9 protein |
CTD |
PMID:25393417 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
multiple interactions |
ISO |
[Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat; Warfarin binds to and results in decreased activity of UGT2B17 protein; Warfarin inhibits the reaction [UGT2B17 protein results in increased glucuronidation of vorinostat] |
CTD |
PMID:25393417 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
[Warfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine; Warfarin binds to and results in decreased activity of UGT2B7 protein; Warfarin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Zidovudine] |
CTD |
PMID:25393417 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 |
decreases expression |
ISO |
Warfarin results in decreased expression of USP5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711
|
|
G |
Vcp |
valosin-containing protein |
decreases expression increases expression |
ISO |
Warfarin results in decreased expression of VCP mRNA Warfarin results in increased expression of VCP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Vdr |
vitamin D receptor |
affects response to substance |
ISO |
VDR gene SNP affects the susceptibility to Warfarin |
CTD |
PMID:28262345 PMID:29298995 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects response to substance multiple interactions |
ISO |
VEGFA gene SNP affects the susceptibility to Warfarin epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]]; epigallocatechin gallate promotes the reaction [Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein]]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA mRNA]; Warfarin inhibits the reaction [Hydrogen Peroxide results in increased expression of VEGFA protein] |
CTD |
PMID:31068094 PMID:36162953 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
Warfarin results in decreased expression of VIM protein |
CTD |
PMID:26206560 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
multiple interactions decreases activity affects abundance decreases response to substance affects response to substance affects metabolic processing increases response to substance decreases metabolic processing |
ISO EXP |
[CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin; Warfarin binds to and results in decreased activity of VKORC1 protein; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of vitamin K1 oxide] Warfarin results in decreased activity of VKORC1 protein VKORC1 gene polymorphism affects the abundance of Warfarin VKORC1 3' UTR results in decreased susceptibility to Warfarin; VKORC1 gene mutant form results in decreased susceptibility to Warfarin; VKORC1 gene polymorphism results in decreased susceptibility to Warfarin VKORC1 3' UTR SNP affects the susceptibility to Warfarin; VKORC1 affects the susceptibility to Warfarin; VKORC1 alternative form affects the susceptibility to Warfarin; VKORC1 gene affects the susceptibility to Warfarin; VKORC1 gene mutant form affects the susceptibility to Warfarin; VKORC1 gene polymorphism affects the susceptibility to Warfarin; VKORC1 gene SNP affects the susceptibility to Warfarin; VKORC1 intron polymorphism affects the susceptibility to Warfarin; VKORC1 intron SNP affects the susceptibility to Warfarin; VKORC1 polymorphism affects the susceptibility to Warfarin; VKORC1 promoter polymorphism affects the susceptibility to Warfarin; VKORC1 promoter SNP affects the susceptibility to Warfarin; VKORC1 protein affects the susceptibility to Warfarin; VKORC1 protein polymorphism affects the susceptibility to Warfarin; VKORC1 protein SNP affects the susceptibility to Warfarin; VKORC1 SNP affects the susceptibility to Warfarin Warfarin inhibits the reaction [VKORC1 protein affects the reduction of vitamin K1 oxide] VKORC1 gene mutant form results in decreased susceptibility to Warfarin; VKORC1 protein polymorphism results in decreased susceptibility to Warfarin VKORC1 protein mutant form affects the susceptibility to Warfarin VKORC1 protein affects the metabolism of Warfarin VKORC1 intron polymorphism results in increased susceptibility to Warfarin; VKORC1 protein results in increased susceptibility to Warfarin; VKORC1 results in increased susceptibility to Warfarin VKORC1 gene polymorphism results in decreased metabolism of Warfarin |
CTD |
PMID:14765194 PMID:14765195 PMID:15358623 PMID:15578879 PMID:15630486 PMID:15879509 PMID:15930419 PMID:16270629 PMID:16421894 PMID:16432637 PMID:16611750 PMID:16676068 PMID:16847429 PMID:16879214 PMID:16890578 PMID:16960144 PMID:17048007 PMID:17049586 PMID:17111199 PMID:17329985 PMID:17387222 PMID:17391071 PMID:17456829 PMID:17496169 PMID:17510308 PMID:17764537 PMID:17941040 PMID:17961434 PMID:17995970 PMID:18030307 PMID:18034619 PMID:18240904 PMID:18266023 PMID:18370846 PMID:18523153 PMID:18532998 PMID:18535201 PMID:18542936 PMID:18574025 PMID:18698879 PMID:18776969 PMID:18805772 PMID:19018718 PMID:19135231 PMID:19200363 PMID:19207028 PMID:19300499 PMID:19567378 PMID:19752777 PMID:19942260 PMID:19998810 PMID:20072124 PMID:20073138 PMID:20339978 PMID:20354686 PMID:20375999 PMID:20386359 PMID:20420818 PMID:20553802 PMID:20579077 PMID:20615525 PMID:20637959 PMID:20716240 PMID:20833655 PMID:20842355 PMID:20854800 PMID:21084764 PMID:21110192 PMID:21176721 PMID:21228733 PMID:21270790 PMID:21320153 PMID:21321468 PMID:21326313 PMID:21428138 PMID:21562147 PMID:21590310 PMID:21635147 PMID:21639946 PMID:21681008 PMID:21786578 PMID:21911247 PMID:22040439 PMID:22161100 PMID:22198820 PMID:22248286 PMID:22266406 PMID:22528326 PMID:22533669 PMID:22571356 PMID:22855348 PMID:22907842 PMID:22990331 PMID:23018795 PMID:23061746 PMID:23167228 PMID:23183958 PMID:23208322 PMID:23276529 PMID:23279643 PMID:23571513 PMID:23602689 PMID:23710884 PMID:23800980 PMID:23928358 PMID:23990957 PMID:24399734 PMID:24474498 PMID:24601977 PMID:24750390 PMID:24966969 PMID:24978953 PMID:25042728 PMID:25312789 PMID:25652102 PMID:25699611 PMID:25747538 PMID:25885753 PMID:25946405 PMID:25986145 PMID:26167638 PMID:26219158 PMID:26223945 PMID:26257249 PMID:26418980 PMID:26445138 PMID:26568290 PMID:26583785 PMID:26644206 PMID:26757860 PMID:26940072 PMID:26996562 PMID:27055637 PMID:27117082 PMID:27258224 PMID:27262824 PMID:27488176 PMID:27622442 PMID:27632229 PMID:27743182 PMID:27938396 PMID:28079798 PMID:28083852 PMID:28135054 PMID:28262345 PMID:28401802 PMID:28550460 PMID:28686080 PMID:28689179 PMID:28867752 PMID:29182754 PMID:29234073 PMID:29581108 PMID:29776386 PMID:30647445 PMID:30883300 PMID:31064211 PMID:31173123 PMID:31395958 PMID:31720756 PMID:31854268 PMID:31869433 PMID:31973625 PMID:32219822 PMID:32669629 PMID:34382722 PMID:34729928 PMID:36476275 PMID:36789833 More...
|
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vkorc1l1 |
vitamin K epoxide reductase complex, subunit 1-like 1 |
multiple interactions |
ISO EXP |
Warfarin affects the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide]; Warfarin binds to and results in decreased activity of VKORC1L1 protein; Warfarin inhibits the reaction [VKORC1L1 protein results in increased metabolism of vitamin K1 oxide]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of vitamin K1 oxide] |
CTD |
PMID:23710884 PMID:23928358 PMID:29581108 |
|
NCBI chr12:26,717,959...26,768,193
Ensembl chr12:26,623,976...26,768,225
|
|
G |
Ywhae |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon |
increases expression |
ISO |
Warfarin results in increased expression of YWHAE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
decreases expression |
ISO |
Warfarin results in decreased expression of ZEB1 protein |
CTD |
PMID:26206560 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|